Novavax Inc (NVAX) is a publicly traded Healthcare sector company. As of May 21, 2026, NVAX trades at $9.25 with a market cap of $1.47B and a P/E ratio of -17.12. NVAX moved +4.33% today. Year to date, NVAX is +27.86%; over the trailing twelve months it is +20.70%. Its 52-week range spans $5.01 to $15.22. Analyst consensus is neutral with an average price target of $11.60. Rallies surfaces NVAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Novavax Reports $140M Q1 Revenue and $30M Pfizer Matrix-M Upfront: Novavax reported $140M Q1 revenue, including a $30M upfront from a Matrix-M license with Pfizer that could generate $500M in milestones plus royalties. The company secured MTAs with four top-10 pharma covering 30+ fields in a $100B infectious disease and oncology market and reaffirmed a $325M 2026 R&D/SG&A expense guide.
| Metric | Value |
|---|---|
| Price | $9.25 |
| Market Cap | $1.47B |
| P/E Ratio | -17.12 |
| EPS | $-0.54 |
| Dividend Yield | 0.11% |
| 52-Week High | $15.22 |
| 52-Week Low | $5.01 |
| Volume | 4.37M |
| Avg Volume | 0 |
| Revenue (TTM) | $596.34M |
| Net Income | $-87.83M |
| Gross Margin | 84.97% |
5 analysts cover NVAX: 0 strong buy, 2 buy, 1 hold, 2 sell, 0 strong sell. Consensus rating is neutral. Average price target: $11.60.